Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure
| Autor: | Raziya Bobat, Werner Schimana, Patrick Jean-Philippe, Tammy Meyers, Mutsawashe Bwakura-Dangarembizi, Paul Palumbo, Mark F. Cotton, Linda Millar, Michael Hughes, Lynne M. Mofenson, Lynette Purdue, Philippa Musoke, Portia Kamthunzi, Elaine J. Abrams, Susan H. Eshleman, Elizabeth Petzold, Avy Violari, Benjamin H. Chi, Jane C. Lindsey |
|---|---|
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | New England Journal of Medicine. 363:1510-1520 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejmoa1000931 |
| Popis: | Background Single-dose nevirapine is the cornerstone of the regimen for prevention of mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings, but nevirapine frequently selects for resistant virus in mothers and children who become infected despite prophylaxis. The optimal antiretroviral treatment strategy for children who have had prior exposure to single-dose nevirapine is unknown. Methods We conducted a randomized trial of initial therapy with zidovudine and lamivudine plus either nevirapine or ritonavir-boosted lopinavir in HIV-infected children 6 to 36 months of age, in six African countries, who qualified for treatment according to World Health Organization (WHO) criteria. Results are reported for the cohort that included children exposed to single-dose nevirapine prophylaxis. The primary end point was virologic failure or discontinuation of treatment by study week 24. Enrollment in this cohort was terminated early on the recommendation of the data and safety ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|